发现了一种选择性和生物活性的人类介质素-1β的低分子量对手
Ulrich Hommel1, Konstanze Hurth2, Jean-Michel Rondeau3
1Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002, Basel, Switzerland. uli.hommel@icloud.com.
Nature communications
|September 7, 2023
概括
研究人员发现了一种新的小分子,可以阻断人体中白蛋白-1β (hIL-1β),这是炎症中的关键蛋白质. 这种口服药物候选药物为治疗由hIL-1β驱动的疾病提供了一个有希望的新途径.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 人间白内素-1β (hIL-1β) 是一种促炎性细胞因子,与各种疾病有关.
- 目前的hIL-1β疗法,主要以抗体为基础,具有临床益处,但缺乏口服可用的小分子抗剂,限制治疗选择.
研究的目的:
- 发现和描述一种新型的低分子量抗体,用于人类介质蛋白-1β (hIL-1β).
- 要识别阻断hIL-1β及其受体IL-1R1.1.之间的相互作用的化合物,IL-1R1.1.
主要方法:
- 基于碎片的选,以识别最初的结果.
- 基于结构的优化,以开发高亲和度化合物.
- 生物物理,生物化学和细胞测试以评估对抗剂活性.
- 进行X射线晶体学以阐明结合方式和作用机制.
主要成果:
- 一种低分子量化合物 (S) - 2 通过基于结构的优化开发出了一个碎片.
- (S)-2表现出单位微分子活性,有效结合和对抗hIL-1β.
- X射线分析揭示了一种针对hIL-1β的新型结合部位的全抑制机制,涉及结构动态区域.
结论:
- 对 (S) - 2的发现代表了口服可用的hIL-1β抗剂的开发的重大进展.
- 已确定的全结合位和结合机制为治疗干预提供了一个新的目标.
- 这种口服活性化合物在细胞模型中显示出有效性,突出显示了它对未来hIL-1β导向疗法的潜力.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
168
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
168
01:24T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
343
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
343